RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

被引：0

作者：

Emma Nolan

François Vaillant

Daniel Branstetter

Bhupinder Pal

Göknur Giner

Lachlan Whitehead

Sheau W Lok

Gregory B Mann

Kathy Rohrbach

Li-Ya Huang

Rosalia Soriano

Gordon K Smyth

William C Dougall

Jane E Visvader

Geoffrey J Lindeman

机构：

[1] Walter and Eliza Hall Institute of Medical Research (WEHI),ACRF Stem Cells and Cancer Division

[2] University of Melbourne,Department of Medical Biology

[3] Amgen Inc.,Department of Pathology

[4] Walter and Eliza Hall Institute of Medical Research,Bioinformatics Division

[5] Imaging Laboratory,Systems Biology and Personalized Medicine Division

[6] Walter and Eliza Hall Institute of Medical Research,Department of Medical Oncology

[7] Familial Cancer Centre,Department of Surgery

[8] Royal Melbourne Hospital,Department of Mathematics and Statistics

[9] Royal Melbourne Hospital,Department of Medicine

[10] The Breast Service,undefined

[11] Royal Melbourne Hospital and Royal Women's Hospital,undefined

[12] University of Melbourne,undefined

[13] University of Melbourne,undefined

[14] Therapeutic Innovation Unit,undefined

[15] Amgen Inc.,undefined

[16] University of Melbourne,undefined

[17] Familial Cancer Centre,undefined

[18] Victorian Comprehensive Cancer Centre,undefined

[19] Present addresses: Cynosure Clinical Research LLC,undefined

[20] North Bend,undefined

[21] Washington,undefined

[22] USA (D.B.); Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute,undefined

[23] Herston,undefined

[24] Queensland,undefined

[25] Australia (W.C.D.).,undefined

来源：

Nature Medicine | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A new study by Jane Visvader, Geoff Lindeman and colleagues reports on the potential role of RANK signaling in pre-neoplastic breast tissue from BRCA1-mutation carriers and in a mouse model of Brca1-deficient mammary cancer, suggesting that targeting RANK could be explored as an approach to prevent growth of tumors harboring mutated BRCA1.

引用

页码：933 / 939

页数：6

共 50 条

[21] Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K
Lynch, HT
Chadirian, P
Tung, N
Olivotto, V
Warner, E
Olopade, OI
Eisen, A
Weber, B
McLennan, J
Sun, P
Foulkes, WD
Narod, SA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2328 - 2335
[22] Prognosis of BRCA1 and BRCA2 mutation carriers with breast cancer
Rennert, G
Bisland-Becktell, S
Almog, R
Zhang, S
Rennert, HS
Narod, S
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (02) : 221 - 221
[23] Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
Warner, Ellen
CANCERS, 2018, 10 (12)
[24] Increased risk of contralateral breast cancer for BRCA1 mutation carriers compared to BRCA2 mutation carriers
Graeser, M.
Engel, C.
Zaino, M.
Schmutzler, R.
ONKOLOGIE, 2008, 31 : 28 - 28
[25] Contralateral Breast Cancer in BRCA 1 vs 2 Mutation Carriers
Girardi, A.
Corso, G.
Magnoni, F.
De Scalzi, A. M.
Tagliaferri, V.
Bottazzoli, E.
Bianchi, B.
Veronesi, P.
BREAST, 2023, 68 : S78 - S78
[26] Survival in Norwegian BRCA1 mutation carriers with breast cancer
Hagen, Anne Irene
Tretli, Steinar
Maehle, Lovise
Apold, Jaran
Veda, Nina
Moller, Pal
HEREDITARY CANCER IN CLINICAL PRACTICE, 2009, 7
[27] Management of breast cancer in BRCA1/2 mutation carriers
Eeles, RA
Camplejohn, R
Peacock, J
McMillan, T
DISEASE MARKERS, 1999, 15 (1-3) : 204 - 204
[28] AURKA and breast cancer in BRCA1/2 mutation carriers
Bodvarsdottir, Sigridur K.
Vidarsdottir, Linda
Eyfjord, Jorunn E.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (11) : 2517 - 2517
[29] Survival in Norwegian BRCA1 mutation carriers with breast cancer
Anne Irene Hagen
Steinar Tretli
Lovise Mæhle
Jaran Apold
Nina Vedå
Pål Møller
Hereditary Cancer in Clinical Practice, 7
[30] Breast tumor location in BRCA mutation carriers and implications for prevention
Hosseini, Ava
Esserman, Laura J.
Wallace, Anne M.
Au, Alfred
Mukhtar, Rita A.
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →